Cite
HARVARD Citation
Guiñazú, J. et al. (n.d.). 121. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Immunogenic. Open forum infectious diseases. pp. S188-S189. [Online].